Novo Holdings invests in biotech company for third time

A number of well-known life science actors have again invested in Amolyt Pharma, and Novo Holdings becomes a main shareholder.

Naveed Siddiqi, board director of Amolyt and senior partner at Novo Holdings, says Amolyt "is a great example of a high quality, late stage private European company." | Photo: Novo Ventures / PR

by andreas lønstrup, translated by daniel pedersen

Novo Holdings has invested, for the third time, in French-American biotech company Amolyt pharma, which develops therapies against endocrine disorders, the investment company reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Ascendis Pharma to enter new disease area with eye disorder candidate
For subscribers
Novo Holdings invests in US-based gene-editing company
For subscribers
Novo Holdings invests in Danish medtech firm
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr

Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix

Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers

Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

Foto: Yuriko Nakao/Reuters/Ritzau Scanpix

Medtech

Olympus appoints new chief medical officer

For subscribers

Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

For subscribers

Vaccine breakthrough behind mRNA shots wins Nobel Prize
The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.
For subscribers
WS Audiology hires new chief technology officer from car manufacturer
He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.
For subscribers
Novo Nordisk files lawsuit against US authorities ahead of price negotiation
The litigation is the latest in a long line of industry lawsuits related to price negotiations.
For subscribers
FDA rejects atopic dermatitis drug lebrikizumab
Eli Lilly had expected a launch this year.
For subscribers
FDA updates Novo Nordisk's Ozempic drug label with side effect alert
The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.
For subscribers
Investment bank: Novo Nordisk's patent victory is a small victory as price negotiations loom
The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.
For subscribers

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Pharma & biotech